April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Incidence of Glaucomatous Visual Field Loss Subsequent to Initial Glaucomatous Optic Disc Deterioration in the Ocular Hypertension Treatment Study (OHTS)
Author Affiliations & Notes
  • M. A. Kass
    Ophthalmology,
    Washington Univ Sch of Med, St Louis, Missouri
  • M. O. Gordon
    Ophthal & Vis Sciences,
    Washington Univ Sch of Med, St Louis, Missouri
  • J. A. Huecker
    Ophthalmology,
    Washington Univ Sch of Med, St Louis, Missouri
  • J. Keltner
    Ophthalmology, University of california Davis, Sacramento,, California
  • R. Parrish
    Ophthalmology, Bascom Palmer Eye Institue, Miami, Florida
  • C. A. Johnson
    Ophthal & Visual Sci, University of Iowa, Iowa City, Iowa
  • Ocular Hypertension Study Group (OHTS)
    Washington Univ Sch of Med, St Louis, Missouri
  • Footnotes
    Commercial Relationships  M.A. Kass, None; M.O. Gordon, None; J.A. Huecker, None; J. Keltner, None; R. Parrish, None; C.A. Johnson, None.
  • Footnotes
    Support  Supported by grants from NEI & Natl Ctr on Minority Health & Health Disparities, NIH (EY09341, 09307, & Core Grant 062687), Merck, White House Station, Pfizer & unrestricted grant from RPB
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2047. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. A. Kass, M. O. Gordon, J. A. Huecker, J. Keltner, R. Parrish, C. A. Johnson, Ocular Hypertension Study Group (OHTS); Incidence of Glaucomatous Visual Field Loss Subsequent to Initial Glaucomatous Optic Disc Deterioration in the Ocular Hypertension Treatment Study (OHTS). Invest. Ophthalmol. Vis. Sci. 2010;51(13):2047. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To determine the incidence of glaucomatous visual field loss subsequent to a primary glaucomatous optic disc endpoint in the Ocular Hypertension Treatment Study (OHTS)

 
Methods:
 

Humphrey visual fields were done every 6 months and stereoscopic optic disc photographs were taken every 12 months. These were reviewed by masked graders in reading centers. An incident case of POAG required 3 consecutive abnormal visual fields or 2 consecutive stereophotographs showing progression that was then attributed to glaucoma by a masked Endpoint Committee. After development of POAG, participants in the observation group initiated ocular hypotensive treatment and participants in the medication group continued treatment. From 2/94 to approximately 6/02, 84 participants developed glaucomatous optic disc deterioration, 59 developed glaucomatous visual field abnormalities and 12 developed both glaucomatous visual field and optic disc deterioration in the same eye. This report includes participants who developed either visual field or optic disc POAG endpoint but not both in the same eye. We report the incidence of POAG visual field abnormality subsequent to initial POAG optic disc deterioration in the same eye and conversely, the incidence of POAG optic disc deterioration subsequent to initial POAG visual field abnormalities in the same eye.

 
Results:
 

Median follow-up after the initial diagnosis of POAG was 7.9 years. The Incidence of POAG endpoints subsequent to the initial optic disc or visual field POAG endpoint is reported in the table below.

 
Conclusions:
 

Despite medical treatment, a substantial proportion of eyes in which glaucomatous damage is initially detected by either disc progression or visual field abnormality subsequently develop reproducible damage in the other modality.  

 
Clinical Trial:
 

www.clinicaltrials.gov NCT00000125

 
Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • optic disc • visual fields 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×